From Toshiba America Medical Systems Inc.;
the Ultra™ system was developed to help healthcare providers be more competitive by delivering greater patient comfort and a broad range of clinical capabilities, says Anita Bowler, product manager, MRI Business Unit, Toshiba America Medical Systems Inc With its unique, powerful gradient technology, the Ultra™ performs advanced clinical studies and consistently provides high-resolution images that are typically associated with high field MRI systems. At the same time, the Ultra™ offers a truly open feeling that makes patients more relaxed, especially those with claustrophobic tendencies.

Vasovist™ is an albumin-targeted intravascular contrast agent. It is indicated for contrast enhanced MR angiography (CE-MRA) for the visualization of abdominal or limb vessels in patients with suspected or known vascular disease. After IV injection, Vasovist™ binds reversibly to human albumin in plasma, which results in long-lasting increased relaxivity. Imaging from 5 to 50 min is possible. A small unbound portion is, by glomerular filtration, eliminated by the kidneys.
AngioMARK® was the formerly trade name and MS-325 the research name. Currently the phase III clinical trials are completed to determine its efficacy for peripheral vascular disease and coronary artery disease.
In the U.S., EPIX received an approvable letter from the U.S. Food and Drug Administration (FDA) for Vasovist™ in January 2005. In 2009, Epix Pharmaceuticals has sold the U.S., Canadian and Australian rights for its blood pool agent (now named ABLAVAR™), to Lantheus Medical Imaging, Inc..

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m²), or acute renal insufficiency of any severity due to the hepato-renal syndrome or the liver transplantation period.

See also MRI Safety.

From Toshiba America Medical Systems Inc.;
the EXCELART is a superconducting whole body MRI system with a short wide-bore magnet, operating at 1.5 T. It features powerful high-speed gradients with a revolutionary gradient acoustic noise reduction system: Pianissimo. The dramatic reduction of gradient acoustic noise by Pianissimo greatly enhances patient comfort during exams. The standard array platform and a wide range of array coils ensure excellent images. A powerful 64-bit RISC-based computer system and newly developed array processor realize high productivity.

From Toshiba America Medical Systems Inc.;
the EXCELART is a superconducting whole body MRI system with a short wide-bore magnet, operating at 1.5 T. It features powerful high-speed gradients with a revolutionary gradient acoustic noise reduction system: Pianissimo. The dramatic reduction of gradient acoustic noise by Pianissimo greatly enhances patient comfort during exams. The standard array platform and a wide range of array coils ensure excellent images. A powerful 64-bit RISC-based computer system and newly developed array processor realize high productivity.

From Toshiba America Medical Systems Inc.; FLEXART™ series is a 0.5 T superconducting MRI system that has been designed to meet the expanding role of MRI in today's clinical environment. The system utilizes innovative technologies such as digital RF, high speed actively shielded gradients and optimized RF coils which support a wide range of MRI developments.